
Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with *MET*-amplified gastric cancer

## SUPPLEMENTARY MATERIALS



**Supplementary Figure 1:** Duration of treatment and best response for each patient in the (A) dose-escalation and (B) dose-expansion phases. <sup>a</sup>One patient in dose cohort 340 mg/m<sup>2</sup> only had nontarget lesions at baseline. CR = complete response; PD = progression of disease; PR = partial response; SD = stable disease.

Patient	Total c-Met (percentage of cells with 2+ or 3+ intensity)*	<i>MET</i> amplification (%)**
1	93	11
2	75	26
3	85	16
4	93	90
5	0	10
6	50	78
7	1	45
8	95	86
9	0	11
10	85	95

Supplementary Table 1: Total c-Met protein expression (IHC) and respective *MET* amplification in patients in the dose-expansion cohort (n = 10)

\*cMet overexpression is defined when there are  $\geq$  50% of tumor cells with 2+ or 3+ positive membrane stain on immunohistochemistry (IHC).

\*\**MET* amplification is defined when there are  $\geq 10\%$  of cells with > 4 *MET* gene copies, and a cMET/CEP7 ratio  $\geq 2$  as determined by fluorescence *in situ* hybridization.

Supplementary	7 Table 2: Sum	nary of stud	v treatment ex	posure (safe	ty population	on)

	Dose in dose-escalation cohort, mg/m <sup>2</sup>				<b>Dose-expansion cohort</b>	
	260 (N = 6)	340 (N=4)	440 (N = 3)	570 (N = 6)	All patients (N = 19)	Gastric cancer (N = 14)
Median treatment duration (range), weeks Total number of infusions administered (all patients), <i>n</i> Total number of infusions administered per patient, median <i>n</i> (range)	3.5 (2-13)	4.3 (2–11)	4.4 (4–11)	8.9 (4–13)	4.0 (2-38)	5.6 (2-38)
	27	21	19	49	157	133
	3.5 (2-12)	4 (2–11)	4 (4–11)	8.5 (4-12)	4 (2–38)	5.5 (2-38)